Premier Biomedical | BIEI | Profile | Summary
Premier
Biomedical (BIEI) is a research-based company that has acquired
exclusive licenses for patent-pending medications and medical
procedures to develop cures for a significant number of the most
debilitating and often fatal illnesses: ALS, Traumatic Brain Injury,
Multiple Sclerosis, Clinical Depression, Alzheimer’s Disease, Blood
Sepsis, and Cancer. The company is in the process of developing
targeted medicines and procedures and will prove out their superior
efficacy in addressing these diseases and others through laboratory,
hospital, and actual patient applications. At the anticipated
successful conclusion of the clinical trials, contact will be
established with the leading worldwide pharmaceutical firms to
establish the right to market and distribute Premier Biomedical’s
technology products and procedures.
·
The Company’s proprietary Sequential Dialysis Technique and
patented candidate drug Feldetrex are expected to provide
superior efficacy versus existing medications in treating a large
number of the most fatal diseases
o
Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia,
Traumatic Brain Injury, Blood Sepsis, and Cancer
·
The Company has established two outstanding research partnerships
with the University of Texas, El Paso (UTEP) and the Department of
Defense
o
Leverage the substantial infrastructure and resourced capacity of
these organizations to perform experimentation and to engage in
product development in an inexpensive and efficient manner
o
Positive results in animal testing for the Sequential Dialysis
Technique treatment of cancer
o
Initiation of two clinical trials including a trial for Feldetrex
and a trial of the Sequential Dialysis Technique
·
Premier Biomedical is a research-based company that intends to
discover and develop medical treatments targeting the treatment of:
Alzheimer’s Disease, Multiple Sclerosis, ALS, Fibromyalgia,
Traumatic Brain Injury, Blood Sepsis, and Cancer
·
The Company’s proprietary Sequential Dialysis Technique is a
methodology that physically removes the pathophysiologic basis of the
disease, eliminating it without dangerous side effects
o
Superior to current treatments which eliminate the presence of most
illnesses but often with catastrophic or even fatal side effects
o
Targets cancer, Alzheimer’s disease, Multiple Sclerosis, ALS, blood
sepsis, and Traumatic Brain Injury – collectively over $700 billion
market opportunity
·
Developed a proprietary drug candidate Feldetrex as a
potential treatment for Multiple Sclerosis, Fibromyalgia, and
Traumatic Brain Injury
o
Expected to deliver significant relief to patients, while presenting
fewer side effects than other alternate medications
o
The Company was recently granted two US patents for this drug
candidate
o
The annual market size of all proposed market segments for Feldetrex
is $16 billion
·
The Company has established two outstanding research partnerships
with the University of Texas, El Paso (UTEP) and the Department of
Defense
o
Leverage the substantial infrastructure and resourced capacity of
these organizations to perform experimentation and to engage in
product development in an inexpensive and efficient manner
o
Positive results in animal testing for the Sequential Dialysis
Technique treatment of cancer
o
Initiation of two clinical trials including a trial for Feldetrex
and a trial of the Sequential Dialysis Technique
Don't
miss the NEXT premium Alert! Sign-up, Get Alerts,MakeMoney!®
Disclaimer/Disclosure:
we received or expecting compensation from the featured company. Our
firm, principals and staff may own/buy/sell/trade stock/securities of
this company. Always Read the full Disclosure/Disclaimer. Thanks.
If
you would like your company featured or want to learn more, please
don't hesitate to contact
the Editor. editor [@] OTCking.com
Alzheimer’s
Disease, Multiple Sclerosis, ALS, Fibromyalgia, Traumatic Brain
Injury, Blood Sepsis,Cancer,sequential dialysis
techniques,DOD,UNT,UofT,USPTO, NFL,SOCCOR,MILITARY,COMBAT
MISSIONS,PTSD.
